RegulomeX

Company Overview

Snapshot

Founded in April 2024 by Alex Ackerman, RegulomeX operates with 1–10 employees. The company holds one patent and is currently in the Pre-Funding stage. RegulomeX ceased operations in September 2024.

Business overview

RegulomeX is a biotechnology startup focused on decoding the non-coding regions of the human genome using artificial intelligence. The company's core technology, the Regulatory Genome Language Model, leverages generative AI to identify regulatory elements controlling gene expression. This technology aims to provide insights into genetic mechanisms underlying complex diseases, serving the personalized medicine and drug discovery markets within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is RegulomeX's primary focus?

RegulomeX focuses on decoding the non-coding regions of the human genome using advanced artificial intelligence to understand genetic mechanisms underlying complex diseases.

What is the core technology developed by RegulomeX?

RegulomeX's core technology is the Regulatory Genome Language Model, which utilizes generative AI to uncover regulatory elements that control gene expression.

When was RegulomeX founded?

RegulomeX was founded in April 2024.

Who is the founder of RegulomeX?

Alex Ackerman is the Co-founder & CEO of RegulomeX.

What is the current operational status of RegulomeX?

RegulomeX ceased to operate in September 2024.